Galectin Therapeutics Set to Present at Major Investment Event
NORCROSS, Ga. – Galectin Therapeutics, Inc. (NASDAQ: GALT), a pioneer in developing innovative therapeutics targeting galectin proteins, has announced participation in a prominent investment conference. The H.C. Wainwright 27th Annual Global Investment Conference is scheduled to take place shortly, allowing the company to connect with investors and showcase its latest advancements.
Event Details and Presentations
The conference will run from September 8 to September 10, providing an excellent platform for Galectin to present its research and development endeavors. The company’s presentation is set for September 8 at 1:00 PM ET. Notably, interested parties can access a live webcast to follow the presentation and gain insights directly from the leadership team.
One-on-One Meetings Available
In addition to the presentation, key executives, including Joel Lewis, Chief Executive Officer, and Khurram Jamil, M.D., Chief Medical Officer, will be available for one-on-one meetings during the conference. Investors are encouraged to reach out to their H.C. Wainwright representatives to schedule meetings, facilitating deeper discussions on the company's vision and pipeline.
Innovative Therapeutics by Galectin
Galectin Therapeutics is on a mission to transform patient outcomes through the development of new therapies aimed at chronic liver disease and cancer treatment. The company's flagship drug, belapectin, is a carbohydrate-based therapy that targets the galectin-3 protein. This protein plays a crucial role in various inflammatory and fibrotic conditions, making belapectin a critical player in the treatment landscape, especially given its Fast Track designation by the U.S. Food and Drug Administration.
Addressing Significant Medical Needs
The primary focus of Galectin's development pipeline is metabolic dysfunction-associated steatohepatitis (MASH), particularly the severe form that leads to cirrhosis. This condition is recognized as one of the leading medical challenges and presents substantial opportunities for innovative therapies. The company's developments extend to planning combination immunotherapy for advanced head and neck cancers, underscoring their commitment to tackling life-threatening diseases.
Collaborations and Future Directions
As they pursue these ambitious goals, Galectin is keen on establishing partnerships that will enhance the efficiency and effectiveness of their drug development processes. They aim to leverage scientific expertise and build strong relationships with external partners to drive their programs forward.
Staying Informed
For those seeking to know more about Galectin Therapeutics and its innovative approaches, additional information can be found on their dedicated website. The platform offers insights into their research, therapies, and upcoming events, ensuring stakeholders remain informed about developments in the ever-evolving healthcare landscape.
Frequently Asked Questions
What is Galectin Therapeutics known for?
Galectin Therapeutics is recognized for developing therapies targeting galectin proteins, particularly in treating chronic liver diseases and cancer.
When is the presentation at the H.C. Wainwright conference?
The company's presentation is scheduled for September 8 at 1:00 PM ET.
Who will represent Galectin at the conference?
Joel Lewis, Chief Executive Officer, and Khurram Jamil, M.D., Chief Medical Officer, will represent the company at the event.
What is belapectin?
Belapectin is Galectin’s primary drug, aimed at inhibiting the galectin-3 protein, which is involved in various diseases.
How can investors learn more about Galectin Therapeutics?
Investors can learn more by visiting the Galectin Therapeutics website for updates and information on upcoming events.
